Clinical Research

Intercept Pharmaceuticals Inc.

Address
305 Madison Avenue

Sponsor Overview

assignment
5
sponsored trials
science
3
molecules
location_city
31
research centres
public
14
countries
person_search
34
investigators

Specializations

Biliary Atresia and Post-hepatoportoenterostomy

Clinical research in pediatric hepatobiliary disease includes studies in children with biliary atresia after a successful Kasai procedure, with attention to liver transplantation, portal hypertension, and progression to end-stage liver disease.

  • Hepatic encephalopathy
  • Variceal bleeding
  • Ascites
  • Pediatric end-stage liver disease

Research activity in this area centers on clinical outcomes relevant to long-term liver health in a pediatric population with chronic biliary obstruction.

Primary Biliary Cholangitis

Studies in primary biliary cholangitis focus on chronic cholestatic liver disease, with outcomes linked to alkaline phosphatase, bilirubin, and other biochemical markers of biliary injury.

  • Alkaline phosphatase
  • Gamma-glutamyl transferase
  • Transaminases
  • Serum bilirubin

Additional interest includes noninvasive measures of liver fibrosis and established disease severity scores used in PBC monitoring.

Autoimmune and Fibrotic Liver Disease

Clinical research also addresses the broader management of autoimmune cholangitis and fibrotic liver disease, with emphasis on biochemical response and markers associated with chronic cholestasis.

  • Liver fibrosis assessment
  • Noninvasive elastography
  • ELF score
  • GLOBE score

These studies reflect a therapeutic interest in conditions where persistent bile flow impairment contributes to progressive liver injury.

Severe Alcohol-Associated Hepatitis

Research in severe alcohol-associated hepatitis focuses on acute inflammatory liver injury and disease progression in patients with advanced alcohol-related liver damage.

  • Alcohol-related hepatitis
  • Disease progression
  • Inflammatory liver injury
  • Cholestatic dysfunction

This area extends the sponsor’s clinical interest into severe liver disorders with significant risk of deterioration and poor hepatic outcomes.

Sponsored Trials

Trial Name Country Status
Efficacy and Safety of Obeticholic Acid in Pediatric Patients with Biliary Atresia Post-Hepatoportoenterostomy: A Randomized, Double-Blind, Placebo-Controlled StudyBelgium BelgiumFrance FranceGermany GermanyItaly ItalyPoland PolandSpain SpainThe Netherlands The NetherlandsNot Yet Recruiting
Evaluation of Bezafibrate and Obeticholic Acid Combination Therapy on Alkaline Phosphatase Levels in Primary Biliary Cholangitis PatientsItaly ItalyNot Recruiting
Evaluation of INT-787 in Severe Alcohol-Associated Hepatitis: A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation StudyFrance FranceNot Recruiting
Evaluation of the Efficacy and Safety of Obeticholic Acid and Bezafibrate in Patients with Primary Biliary Cholangitis Unresponsive or Intolerant to Ursodeoxycholic AcidBelgium BelgiumCroatia CroatiaCzechia CzechiaEstonia EstoniaFrance FranceGermany GermanyGreece GreeceHungary HungaryLithuania LithuaniaNorway NorwaySpain SpainThe Netherlands The NetherlandsNot Recruiting
Long-Term Safety and Tolerability of Obeticholic Acid and Bezafibrate in Primary Biliary Cholangitis: A Phase 3 Open-Label Extension StudyBelgium BelgiumCroatia CroatiaCzechia CzechiaEstonia EstoniaFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyLithuania LithuaniaNorway NorwayThe Netherlands The NetherlandsNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
2
Exclusive Molecules
out of 3 total (67% not shared with other sponsors)

This sponsor works with 3 molecules, of which 2 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
48%
Return partnership rate
15 of 31 sites collaborated multiple times

This sponsor has worked with 31 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Digestive System Diseases3 trials
    280 other sponsors
  • 2.
    Digestive System and Oral Physiological Phenomena1 trial
    16 other sponsors
  • 3.
    Nutritional and Metabolic Diseases1 trial
    211 other sponsors

Partnered Research Centres

31 centres
location_city
assignment185
Akershus University Hospital
Address
Sykehusveien 25, 1474 Lorenskog
Learn morearrow_forward
location_city
assignment680
Amsterdam UMC
Address
De Boelelaan 1117, 1081 HV Amsterdam
Learn morearrow_forward
location_city
assignment16
Artroscan s.r.o.
Address
Trebovicka 5114/106, 722 00 Trebovice
Learn morearrow_forward
location_city
assignment338
Azienda Ospedaliera Papa Giovanni XXIII
Address
Piazza Oms 1, 24127 Bergamo
Learn morearrow_forward
location_city
assignment714
Azienda Unita Sanitaria Locale Di Bologna
Address
Via Pietro Albertoni 15, 40138 Bologna
Learn morearrow_forward
location_city
assignment1199
Centre Hospitalier Lyon Sud
Address
165 Chemin Du Grand Revoyet, 69310 Pierre Benite
Learn morearrow_forward
Page 1 of 6

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Intercept Pharmaceuticals Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.